About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Transcatheter Aortic Valve Implantation as Effective as Surgery in Intermediate Patients

by Bidita Debnath on March 19, 2017 at 12:22 AM
Font : A-A+

 Transcatheter Aortic Valve Implantation as Effective as Surgery in Intermediate Patients

Medtronic plc (NYSE: MDT) unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented at the American College of Cardiology (ACC) 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine (NEJM).

Data from the trial showed the Medtronic self-expanding TAVR platform met its primary endpoint of all-cause mortality or disabling stroke at two years. Rates of all-cause mortality or disabling stroke at two years were similar to surgical aortic valve replacement (SAVR) (12.6 percent for TAVR versus 14.0 percent for SAVR; posterior probability of non-inferiority >0.999). The minimally-invasive TAVR procedure also demonstrated significantly better mean aortic valve gradient (7.8 mm Hg vs. 11.8 mm Hg; p<0.001) at two years, while neither TAVR- nor SAVR-treated patients displayed evidence of structural valve deterioration at two years.

Advertisement


"We observed excellent outcomes in both arms of the study and were pleased to see the self-expanding platform perform as well as the gold standard of surgery in this intermediate risk patient population," said Michael Reardon, M.D., professor of cardiothoracic surgery and Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist DeBakey Heart & Vascular Center, principal investigator and author of the SURTAVI trial. "Importantly, near-term results showed critical insights for the therapy. In the first 30 days, patients treated with TAVR experienced statistically lower rates of stroke, lower rates of new onset atrial fibrillation, a quicker hospital discharge, less acute kidney injury and transfusions, and an improved quality of life. SAVR was associated with less aortic regurgitation, major vascular complications and need for permanent pacemaker implantation."

The SURTAVI trial is a global, prospective, multi-center, randomized study evaluating the Medtronic CoreValve(TM) System and CoreValve(TM) Evolut(TM) R System versus open-heart surgery at two years. The SURTAVI trial enrolled intermediate risk patients and compared 863 TAVR patients (STS: 4.4 percent) to 794 SAVR patients (STS: 4.5 percent).
Advertisement

"This is a landmark trial demonstrating our commitment to generating clinical evidence to support the expansion of global patient access to life-changing therapies such as TAVR," said Rhonda Robb, vice president and general manager of the Heart Valve Therapies business, which is part of the Cardiac and Vascular Group at Medtronic. "We are delighted to have met the primary endpoint in the SURTAVI trial, the results of which have been submitted to the FDA to support an intermediate risk label expansion."

The use of the CoreValve and Evolut R systems in intermediate risk severe aortic stenosis patients is investigational only in the U.S.

Following the launch of the self-expanding CoreValve System in the U. S. in 2014, the CoreValve Evolut R System became the first-and-only recapturable and repositionable TAVR device approved in the U.S. for severe aortic stenosis patients at a high or extreme risk for surgery in 2015. The Evolut R system received CE (Conformité Européene) Mark for intermediate risk severe aortic stenosis patients in 2016.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Sugar Intake and Oral Health
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Aortic Valve Stenosis Bicuspid Aortic Valve 

Most Popular on Medindia

Nutam (400mg) (Piracetam) Diaphragmatic Hernia Selfie Addiction Calculator Blood Pressure Calculator Turmeric Powder - Health Benefits, Uses & Side Effects A-Z Drug Brands in India How to Reduce School Bag Weight - Simple Tips Accident and Trauma Care Indian Medical Journals Drug Side Effects Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Transcatheter Aortic Valve Implantation as Effective as Surgery in Intermediate Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests